Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma

Abstract

<i>TP53</i>^mut ctDNA shows potential as a tumor-specific biomarker for treatment response monitoring in HGSOC. <i>TP53</i>^mut ctDNA levels at 3 months post treatment has a significant prognostic utility than that of CA 125.